Last updated: March 9, 2026
What is the Product?
NDC 64980-0511 is the label identifier for Sage Therapeutics' (Sage) Zulresso (zuranolone), indicated for the treatment of postpartum depression. Zulresso received FDA approval in June 2019. It is the first FDA-approved drug specifically indicated for postpartum depression.
Market Landscape
Market Size and Epidemiology
- Postpartum depression (PPD) affects roughly 10–15% of women after childbirth, equating to approximately 2 million cases annually in the U.S.
- The total addressable market in the U.S. is estimated at approximately $1.5 billion annually, considering drug adoption rates and reimbursement practices.
Competitive Environment
- Currently, Zulresso is the only FDA-approved drug targeting PPD.
- Off-label treatments include SSRIs and therapy, but these are less specific.
- The market share for Zulresso is expected to grow with increasing awareness and broadening of indications.
Regulatory Status and Approvals
- Approved by the FDA in June 2019.
- Currently marketed solely in the U.S., with potential expansion into other regions.
Pricing and Revenue Analysis
Current Pricing Structure
- Initial administration: Approximately $37,000 per infusion.
- Total treatment course: About 60 hours of infusion, often requiring 3 doses in a week.
- Per patient cost: Estimated at $34,000 to $37,000 for complete treatment, depending on dosing adjustments and supportive care.
Reimbursement Policies
- Majority paid via insurance, including Medicaid and commercial plans.
- Reimbursement rates are negotiated, with average payments around $25,000 to $35,000 per treatment course.
Revenue Projections
| Year |
Estimated Patients |
Market Penetration |
Revenue (USD) |
Notes |
| 2023 |
15,000 |
15% |
$450 million |
Steady growth as awareness and diagnosis rates increase. |
| 2024 |
25,000 |
20% |
$900 million |
Pricing remains stable; expanding access and provider familiarity. |
| 2025 |
40,000 |
25% |
$1.2 billion |
Potential price adjustments and expanded indications could influence revenue. |
Assumptions: Growth driven by increased diagnosis, provider education, and favorable insurance coverage. No significant price reductions anticipated in the near term.
Price Trends and Future Projections
Influencing Factors
- Reimbursement pressures: Insurers may seek discounts or value-based contracts.
- Developments in off-label treatments: Competition from generic or alternative therapies could lower prices.
- New entrants: Pending drugs or biosimilars could alter market dynamics and pricing.
Price Outlook
- Short-term (1-2 years): Stable pricing. Expect minor fluctuations within ±10%.
- Mid-term (3-5 years): Potential for slight price reductions if competition emerges. Prices could decline to $30,000–$35,000 per course.
- Long-term: If biosimilars or generics develop, prices might decrease further, but current data do not indicate imminent competition.
Summary
| Aspect |
Data/Estimate |
Commentary |
| Market size |
~$1.5 billion in the U.S. |
Driven by PPD prevalence |
| Current price per course |
~$34,000 to $37,000 |
Paid predominantly through private insurance |
| Projected revenue (2023) |
~$450 million |
Based on 15,000 patients |
| Price trend |
Stable short-term, potential decline mid-term |
Influenced by competition and insurance negotiations |
Key Takeaways
- Zulresso’s market remains relatively nascent but is expected to grow rapidly over the next 2–3 years.
- Pricing is high relative to other antidepressants but justified by targeted therapy and high unmet need.
- Market penetration depends heavily on insurance reimbursement policies and clinician acceptance.
- Price reductions are unlikely in the immediate future; however, significant competitiveness could reshape the landscape over 3–5 years.
- Continued monitoring of regulatory developments, competitor entries, and coverage policies is crucial for accurate forecasting.
FAQs
Q1: How does Zulresso differ from traditional depression drugs?
A1: Zulresso is a neuroactive steroid with fast-acting effects targeting postpartum depression, with infusion-based administration, unlike oral antidepressants.
Q2: What is the likelihood of price reductions in the next 2 years?
A2: Low, unless new competitors or biosimilars enter the market, influencing pricing strategies.
Q3: Are there approved alternatives for postpartum depression?
A3: No FDA-approved alternatives; off-label use of SSRIs exists but lacks the rapid action and targeted indication.
Q4: What factors could accelerate market growth?
A4: Increased screening, insurance reimbursement expansion, and broader indication approvals.
Q5: How might new regulatory actions affect Zulresso’s pricing?
A5: Stricter reimbursement policies could pressure prices downward; conversely, approval of additional indications could increase market size without affecting price.
References
-
U.S. Food and Drug Administration. (2019). FDA approves first drug for postpartum depression. Retrieved from https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-postpartum-depression
-
IQVIA. (2022). Medication access data. Market size estimates.
-
Sage Therapeutics. (2022). Zulresso prescribing information.
-
CMS.gov. (2022). Reimbursement policies for postpartum depression treatments.
-
Statista. (2023). Postpartum depression statistics.
